bioRxiv Channel: IMO Workshop
https://biorxiv.org
This feed contains articles for bioRxiv Channel "IMO Workshop"
bioRxivbioRxiv
https://biorxiv.org
<![CDATA[
Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma
]]>
https://biorxiv.org/cgi/content/short/049072v1?rss=1"
Chandler GatenbeeNuria Folguera-BlascoCharlie DaneilsJill GallaherRuss RockneCasey AdamsMichael NicholsonEleni ManiatiJohn KennedyKimberly LuddyFrederick L. LockeMark Robertson-Tessi2016-04-18doi:10.1101/049072Cold Spring Harbor Laboratory Press2016-04-18
<![CDATA[
Enhancing synergy of CAR T cell therapy and oncolytic virus therapy for pancreatic cancer.
]]>
https://biorxiv.org/cgi/content/short/055988v1?rss=1"
Rachel WalkerPedro E NavasSamuel H FriedmanSimona GallianiAleksandra KarolakFiona MacFarlaneRobert NobleJan PoleszczukShonagh RussellKatarzyna A RejniakAmir ShahmoradiFrederik ZiebellJason BrayerDaniel Abate-DagaHeiko Enderling2016-05-30doi:10.1101/055988Cold Spring Harbor Laboratory Press2016-05-30
<![CDATA[
Toxicity Management in CAR T cell therapy for B-ALL: Mathematical modelling as a new avenue for improvement.
]]>
https://biorxiv.org/cgi/content/short/049908v1?rss=1"
Shalla HansonDavid Robert GrimesJake P. Taylor-KingBenedikt BauerPravnam I. WarmanZiv FrankensteinArtem KaznatcheevMichael J. BonassarVincent L. CannataroZeinab Y. MotaweErnesto A. B. F. LimaSungjune KimMarco L. DavilaArturo Araujo2016-04-22doi:10.1101/049908Cold Spring Harbor Laboratory Press2016-04-22
<![CDATA[
Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy
]]>
https://biorxiv.org/cgi/content/short/085910v1?rss=1"
Buttenschoen, A.Elkenawi, A.El Moustaid, F.Fletcher, A.Grassberger, C.Kim, E.Marusyk, A.McClelland, H.-L.Miroshnychenko, D.Nichol, D.Mullinax, J.O'Farrely, C.Scott, J.2016-11-05doi:10.1101/085910Cold Spring Harbor Laboratory Press2016-11-05
<![CDATA[
Combining radiomics and mathematical modeling to elucidate mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer
]]>
https://biorxiv.org/cgi/content/short/190561v1?rss=1"
Saeed-Vafa, D.Bravo, R.Dean, J. A.El-Kenawi, A.Mon Pere, N.Strobl, M.Daniels, C.Stringfield, O.Damaghi, M.Tunali, I.Brown, L.Curtin, L.Nichol, D.Peck, H.Gillies, R. J.Gallaher, J.2017-09-22doi:10.1101/190561Cold Spring Harbor Laboratory Press2017-09-22
<![CDATA[
Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia
]]>
https://biorxiv.org/cgi/content/short/211151v1?rss=1"
Kaznatcheev, A.Grimes, D. R.Vander Velde, R.Cannataro, V. L.Baratchart, E.Dhawan, A.Liu, L.Myroshnychenko, D.Taylor-King, J. P.Yoon, N.Padron, E.Marusyk, A.Basanta, D.2017-10-30doi:10.1101/211151Cold Spring Harbor Laboratory Press2017-10-30
<![CDATA[
Targeting the Untargetable: Predicting Pramlintide Resistance Using a Neural Network Based Cellular Automata
]]>
https://biorxiv.org/cgi/content/short/211383v1?rss=1"
Kim, E.Schenck, R.West, J.Cross, W.Harris, V.McKenna, J.Cho, H.Coker, E.Lee-Kramer, S.Tsai, K.Flores, E.Gatenbee, C. D.2017-10-30doi:10.1101/211383Cold Spring Harbor Laboratory Press2017-10-30
<![CDATA[
The impact of tumor stromal architecture on therapy response and clinical progression
]]>
https://biorxiv.org/cgi/content/short/451047v1?rss=1"
Altrock, P.Yoon, N.Bull, J. A.Wu, H.Ruiz-Ramirez, J.Miroshnychenko, D.Kimmel, G. J.Kim, E.Vander Velde, R. J.Rejniak, K.Manley, B. J.Spill, F.Marusyk, A.2018-10-24doi:10.1101/451047Cold Spring Harbor Laboratory Press2018-10-24
<![CDATA[
Connecting the Microenvironmental Niche to Treatment Response in Ovarian Cancer
]]>
https://biorxiv.org/cgi/content/short/452052v1?rss=1"
Strobl, M.Wicker, M.Adhikarla, V.Shockey, A.Lakatos, E.Pooladvand, P.Schenck, R.Saputro, L.Gatenby, C.Koppens, M.Cruz Garcia, S.Wenham, R.Damaghi, M.Gallaher, J. A.2018-10-24doi:10.1101/452052Cold Spring Harbor Laboratory Press2018-10-24
<![CDATA[
Evolutionary exploitation of PD-L1 expression in hormone receptor positive breast cancer
]]>
https://biorxiv.org/cgi/content/short/454447v1?rss=1"
West, J.Park, D.Harmon, C.Williamson, D.Ashcroft, P.Maestrini, D.Ardaseva, A.Bravo, R.Sahoo, P.Khong, H.Luddy, K.Robertson-Tessi, M.2018-10-26doi:10.1101/454447Cold Spring Harbor Laboratory Press2018-10-26
<![CDATA[
Overcoming non-small cell lung cancer radiation resistance by modulating the tumor-immune ecosystem
]]>
https://biorxiv.org/cgi/content/short/458372v1?rss=1"
Nizzero, S.Alfonso, J. C. L.Alvarez-Arenas, A.Mirzaev, I.Zervantonakis, I. K.Lewin, T.Rishi, A.Piretto, E.Joshi, T. V.Santiago, D. N.Karolak, A. M.Howard, R.Enderling, H.Karreth, F. A.Torres-Roca, J.2018-11-08doi:10.1101/458372Cold Spring Harbor Laboratory Press2018-11-08
<![CDATA[
Harnessing patient-specific response dynamics to optimize evolutionary therapies for metastatic clear cell renal cell carcinoma - Learning to adapt
]]>
https://biorxiv.org/cgi/content/short/563130v1?rss=1"
Sorribes, I. C.Basu, A.Brady, R.Enriquez-Navas, P. M.Feng, X.Kather, J. N.Nerlakanti, N.Stephens, R.Strobl, M.Tavassoly, I.Vitos, N.Lemanne, D.Manley, B.O'Farrelly, C.Enderling, H.2019-02-28doi:10.1101/563130Cold Spring Harbor Laboratory Press2019-02-28
<![CDATA[
Modeling adaptive therapy in non-muscle invasive bladder cancer
]]>
https://biorxiv.org/cgi/content/short/826438v1?rss=1"
Ferrall-Fairbanks, M. C.Kimmel, G. J.Black, M.Bravo, R.Deac, O.Martinez, P.Myers, M.Nazari, F.Osojnik, A.Subramanian, H.Viossat, Y.Whiting, F.Li, R.Mann, K. M.Altrock, P. M.2019-11-06doi:10.1101/826438Cold Spring Harbor Laboratory Press2019-11-06
<![CDATA[
Interactions between ploidy and resource availability shape clonal interference at initiation and recurrence of glioblastoma
]]>
https://biorxiv.org/cgi/content/short/2023.10.17.562670v1?rss=1"
Nowicka, Z.Rentzeperis, F.Beck, R.Tagal, V.Forero Pinto, A. M.Scanu, E.Veith, T.Cole, J.Ilter, D.Dominguez Viqueira, W.Teer, J. K.Maksin, K.Pasetto, S.Abdalah, M. A.Fiandaca, G.Prabhakaran, S.Schultz, A.Ojwang, M.Barnholtz-Sloan, J. S.Joaquim, F. M.Gomes, A. P.Katira, P.Andor, N.2023-10-20doi:10.1101/2023.10.17.562670Cold Spring Harbor Laboratory Press2023-10-20
<![CDATA[
Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy
]]>
https://biorxiv.org/cgi/content/short/2025.07.10.664235v1?rss=1"
50%), most eventually succumb to their disease due to high recurrence rates, acquired resistance, and cumulative toxicity. This report summarizes work from the 12th IMO Workshop in which we explored an alternative "extinction therapy" strategy for frontline treatment of HGSOC. Inspired by ecological principles, this multi-strike approach aims to eradicate tumors not through a singular "magic bullet" but through a series of therapies after standard frontline treatment when the tumor is still, and perhaps most, vulnerable. We present a framework leveraging mathematical modeling (MM) to develop personalized multi-strike protocols for HGSOC. Key contributions include: 1) An "IMOme" score using liquid biopsy data to assess patient-specific hematopoietic toxicity risk, guiding the timing and selection of subsequent therapies, 2) MM strategies to design effective lowdose combinations of targeted agents to achieve synthetic lethality while managing toxicity, and 3) A MM framework to analyze the interplay between chemotherapy, gut microbiome toxicity, and immunotherapy, demonstrating how mitigating microbiome damage could enhance immune response. Overall, the computational approaches presented herein aim to support the design of personalized, multi-strike regimens in the frontline setting that proactively target tumor extinction while managing toxicity, ultimately seeking to deliver cures for patients with HGSOC.
]]>Gallagher, K.Sousa, R. S.Gatenbee, C. D.Schenck, R.Chen, P.Citak, T.Leither, S.Mazzacurati, L.Xella, A.Zhou, Z.Lemanne, D.Rodriguez, P.George, E.Strobl, M. A. R.2025-07-16doi:10.1101/2025.07.10.664235Cold Spring Harbor Laboratory Press2025-07-16